

REMARKS

The purpose of this Preliminary Amendment is to eliminate multiple dependent claims in order to avoid the additional fee. Applicants reserve the right to reintroduce claims to canceled combined subject matter.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned "**Version With Markings to Show Changes Made**".

Respectfully submitted,



John A. Sopp, Reg. No. 33,103

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

Arlington Courthouse Plaza 1

2200 Clarendon Boulevard, Suite 1400

Arlington, VA 22201

Direct Dial: 703-812-5315

Facsimile: 703-243-6410

Email: sopp@mwzb.com

AJZ(JAS):jmm

FILED: 4 SEPTEMBER 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claims 8, and 10-11 have been amended as follows:

8. (Amended) A DNA coding for a polypeptide of ~~any of the~~ claims 1-7.
10. (Amended) Pharmaceutical preparation comprising a polypeptide according to ~~any of the~~ claims 1-7, where appropriate, together with suitable excipients, carriers and other active ingredients.
11. (Amended) An antibody directed to a polypeptide according to claims 1-7.

004493-09043
"FEB 2000"